Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge

Christin Melton, ELS
Published: Tuesday, Mar 19, 2019
Mark R. Litzow, MD

Mark R. Litzow, MD
Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma (ALL), especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.


New Agents for Philadelphia-Negative ALL

The first element of risk stratification, according to Bijal D. Shah, MD, is determining whether patients are fit enough to receive intensive chemotherapy. Because age is often viewed as a barometer of fitness, fit elderly patients are frequently denied highly toxic, yet potentially curative, therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication